Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Safety and Efficacy Study of ADI-001 Anti-CD20 CAR-engineered Allogeneic Gamma Delta (γδ) T Cells in Adults With B Cell Malignancies

NCT04735471 is registered in ClinicalTrials.gov with Adicet Therapeutics as lead sponsor.

NCT NCT04735471
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04735471 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Safety and Efficacy Study of ADI-001 Anti-CD20 CAR-engineered Allogeneic Gamma Delta (γδ) T Cells in Adults With B Cell Malignancies
Lead sponsor
Adicet Therapeutics
Phase
Phase 1
Overall status
Terminated
Start date
March 4, 2021
Completion date
February 3, 2025
Enrollment
34 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b cell lymphoma, lymphoma, follicular, lymphoma, mantle-cell, lymphoma, non-hodgkin, marginal zone lymphoma, primary mediastinal b-cell lymphoma